Sundeep Das, MD
Interventional Cardiology · Bridgeton, MONPI 1548274749
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (55.5%), food and beverage and other — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Angiodynamics, Inc. at 59.0% of the total. Reporting peaked in 2021 at $12,358 and has fallen 90.5% since, to $1,175 in 2025.
Across 706 payments — averaging $43.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$18K
- Novartis$2K
- Johnson & Johnson$757
- AstraZeneca$555
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$539
- Amgen$515
- plus $8K from 54 others
Across 4 payments — averaging $4618.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bard Peripheral Vascular, Inc.$18K
What the payments were for
- Consulting fees$2191%
- Food & beverage$12,48041%
- Education$16,99256%
- Other$9173%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auryon Laser System 100-120 Vac$10,917
- Auryon$6,806
- OPTIMIZER$356
- Diamondback Coronary$326
- AngioVac$149
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$133
- Edwards SAPIEN 3 Transcatheter Heart Valve$130
- GENERAL VASCULAR INTERVENTION$125
- ELIQUIS$122
- Carto 3$122
- Passeo-18$121
- PRO-Kinetic Energy$121
- Orsiro Mission$121
- PK Papyrus$121
- GENERAL METALLIC STENTS$116
- XARELTO$115
- Barostim Neo System$112
How this compares
$30,608 in reported general payments places this provider in the 75th percentile of 182 interventional cardiology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 419 | $435,161 |
| VyndamaxTafamidis | 14 | $308,616 |
| JardianceEmpagliflozin | 291 | $279,353 |
| XareltoRivaroxaban | 265 | $252,008 |
| EntrestoSacubitril/Valsartan | 194 | $233,551 |
| Repatha SureclickEvolocumab | 197 | $180,539 |
| OzempicSemaglutide | 88 | $122,284 |
| FarxigaDapagliflozin Propanediol | 77 | $83,507 |
| MounjaroTirzepatide | 72 | $71,693 |
| Bosentan | 13 | $58,870 |
| WegovySemaglutide | 28 | $40,737 |
| Ambrisentan | 12 | $33,958 |
| CorlanorIvabradine Hcl | 42 | $33,900 |
| MultaqDronedarone Hcl | 14 | $25,305 |
| Ranolazine ErRanolazine | 237 | $24,156 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Vyndamax | $411 | $743,777433 claims |
| Boehringer IngelheimJardiance | $475 | $279,353291 claims |
| Johnson & JohnsonXarelto | $757 | $252,008265 claims |
| NovartisEntresto | $1,730 | $233,551194 claims |
| Novo NordiskOzempic, Wegovy | $152 | $163,021116 claims |
| AstraZenecaFarxiga | $555 | $83,50777 claims |
| Lilly USA, LLCMounjaro | $77 | $71,69372 claims |
| Actelion Pharmaceuticals US, Inc.Bosentan | $327 | $58,87013 claims |
| AmgenCorlanor | $515 | $33,90042 claims |
| Sanofi-aventis U.S. LLCMultaq | $249 | $25,30514 claims |
| BayerKerendia | $279 | $14,54916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 182 interventional cardiology providers in Missouri.
Other interventional cardiology in Bridgeton
- Shariq ShamimBridgeton$18K
- Joshua StolkerWashington$1.2M
- John LasalaSaint Louis$936K
- Harvey SerotaSaint Louis$752K
- Jasvindar SinghSaint Louis$696K
- Gerald MancusoKansas City$402K
- James GranthamKansas City$357K
- Matthew BunteKansas City$242K
- Alan ZajariasSaint Louis$203K
- Anish ThomasSaint Louis$171K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.